Articles related to AMBULATORY CARE

Any New Ink? Revisiting Guidance on Anesthesia for Tattoos

As sedation and anesthesia for extensive tattooing draw greater attention, questions about credentialing, facility standards, prolonged procedures, local anesthetic toxicity, and regulatory oversight remain unsettled across practice settings.

Anesthesiology October 16th 2026

Tags: AMBULATORY CARE BODY AESTHETICS PATIENT SAFETY PERIOPERATIVE CARE REGULATORY AFFAIRS RISK MANAGEMENT

Medical Professionals Reference (MPR)

FDA Approves Moderna’s Next-Generation COVID-19 Vaccine mNexspike

Higher vaccine efficacy (13.5% [95% CI, -7.7, 30.6]) was observed with mNexspike vs the comparator in individuals aged 65 years and older.

Clinical Pharmacology September 3rd 2025

Tags: AMBULATORY CARE COMMUNITY PHARMACY COVID-19 DEVICE/DRUG APPROVALS FDA VACCINES/IMMUNIZATION

Pharmacy Times

FDA Approves Bildyos and Bilprevda, Biosimilars of Reference Denosumab

Comprehensive data package, including structural and functional analytical data, clinical pharmacokinetic data, and a comparative clinical study demonstrating that Bildyos and Bilprevda are highly similar to and have no clinically meaningful differences from their reference products.

Clinical Pharmacology September 3rd 2025

Tags: AMBULATORY CARE BIOSIMILARS BONE HEALTH ONCOLOGY PHARMACY OSTEOPOROSIS SUPPORTIVE ONCOLOGY CARE

Specialty Pharmacy Continuum

Pharmacist-Managed Diabetes Program Slashes HbA1c Levels

The average change in HbA1c from initial visit to discharge was –2.68% in patients who graduated and –0.47% in those who were discharged—quite significant, given that every 1% reduction in HbA1c translates into a 14% decrease in the risk for heart attack.

Clinical Pharmacology September 3rd 2025

Tags: AMBULATORY CARE COLLABORATIVE CARE HEALTH EQUITY HEALTHCARE DISPARITIES TYPE 2 DIABETES

Trending Topics:

Articles related to AMBULATORY CARE

Any New Ink? Revisiting Guidance on Anesthesia for Tattoos

FDA Approves Moderna’s Next-Generation COVID-19 Vaccine mNexspike

FDA Approves Bildyos and Bilprevda, Biosimilars of Reference Denosumab

Pharmacist-Managed Diabetes Program Slashes HbA1c Levels

Topics

Sources

The Healthcare Communications Network is owned and operated by IQVIA Inc. Click below to leave this site and continue to IQVIA’s Privacy Choices form

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form